List of antiretroviral fixed-dose combinations
Antiretroviral drugs are used to manage HIV/AIDS. Multiple antiretroviral drugs are often combined into a single pill in order to reduce pill burden.
Some of these combinations are complete single-tablet regimens; the others must be combined with additional pills to make a treatment regimen.
Brand name(s) | Ingredients (INN) | Food and Drug Administration (FDA) approval date | European Medicines Agency (EMA) approval date | Health Canada approval date | Company | Single-tablet regimen? | ||||
NRTIs / NtRTIs | NNRTI | INSTI | PI | PK enhancer | ||||||
Combivir | lamivudine zidovudine | September 26, 1997 | ViiV Healthcare | No | ||||||
Kaletra (developed countries) Aluvia (developing countries) | lopinavir | ritonavir | September 15, 2000 | Abbott Laboratories | No | |||||
Trizivir | abacavir lamivudine zidovudine | November 15, 2000 | ViiV Healthcare | Yes | ||||||
Epzicom (US) Kivexa (EU, RU) | abacavir lamivudine | August 2, 2004 | ViiV Healthcare | No | ||||||
Generics, e.g., Triomune | lamivudine stavudine | nevirapine | (not approved) | (many companies) | Yes | |||||
Generics, e.g., Duovir-N | lamivudine zidovudine | nevirapine | (not approved) | (many companies) | Yes | |||||
Truvada | emtricitabine tenofovir disoproxil | August 2, 2004 | Gilead Sciences | No | ||||||
Atripla | emtricitabine tenofovir disoproxil | efavirenz | July 12, 2006 | Gilead Sciences Bristol-Myers Squibb | Yes | |||||
Complera (US) Eviplera (EU, RU) | emtricitabine tenofovir disoproxil | rilpivirine | August 10, 2011 | Gilead Sciences Janssen Pharmaceutica | Yes | |||||
Stribild | emtricitabine tenofovir disoproxil | elvitegravir | cobicistat | August 27, 2012 | Gilead Sciences | Yes | ||||
Triumeq | abacavir lamivudine | dolutegravir | August 22, 2014 | ViiV Healthcare | Yes | |||||
Evotaz | atazanavir | cobicistat | January 29, 2015 | Bristol-Myers Squibb | No | |||||
Prezcobix (US) Rezolsta (EU) | darunavir | cobicistat | January 29, 2015 | Janssen Pharmaceutica | No | |||||
Dutrebis | lamivudine | raltegravir | February 6, 2015 | Merck & Co. | No | |||||
Genvoya | emtricitabine tenofovir alafenamide | elvitegravir | cobicistat | November 5, 2015 | Gilead Sciences | Yes | ||||
Odefsey | emtricitabine tenofovir alafenamide | rilpivirine | March 1, 2016 | Gilead Sciences | Yes | |||||
Descovy | emtricitabine tenofovir alafenamide | April 4, 2016 | Gilead Sciences | No | ||||||
Juluca | rilpivirine | dolutegravir | November 21, 2017 | ViiV Healthcare | Yes | |||||
Symfi, Symfi Lo | lamivudine tenofovir disoproxil | efavirenz | February 5, 2018 (Symfi Lo) March 22, 2018 (Symfi) | Mylan | Yes | |||||
Biktarvy | emtricitabine tenofovir alafenamide | bictegravir | February 7, 2018 | Gilead Sciences | Yes | |||||
Cimduo, Temixys | lamivudine tenofovir disoproxil | February 28, 2018 | Mylan | No | ||||||
Symtuza | emtricitabine tenofovir alafenamide | darunavir | cobicistat | July 17, 2018 | Janssen Pharmaceutica | Yes | ||||
Delstrigo | lamivudine tenofovir disoproxil | doravirine | August 30, 2018 | Merck & Co. | Yes | |||||
Dovato | lamivudine | dolutegravir | April 8, 2019 | ViiV Healthcare | Yes | |||||
Cabenuva | rilpivirine | cabotegravir | January 21, 2021 | March 18, 2020[1][2] | ViiV Healthcare | No |
References
External links
- "Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets". ClinicalInfo. This article incorporates text from this source, which is in the public domain.
- v
- t
- e
(Discovery and development)
(Integrase strand transfer inhibitors (INSTI))
(Discovery and development)
1st generation | |
---|---|
2nd generation |
inhibitors (RTIs)
Nucleoside and nucleotide (NRTI) | |||||
---|---|---|---|---|---|
Non-nucleoside (NNRTI) (Discovery and development) |
|
- Abacavir/lamivudine#
- Abacavir/dolutegravir/lamivudine°
- Abacavir/lamivudine/zidovudine
- Atazanavir/cobicistat
- Bictegravir/emtricitabine/tenofovir alafenamide°
- Cabotegravir/rilpivirine
- Darunavir/cobicistat
- Darunavir/cobicistat/emtricitabine/tenofovir alafenamide°
- Dolutegravir/emtricitabine/tenofovir alafenamide
- Dolutegravir/lamivudine°
- Dolutegravir/lamivudine/tenofovir alafenamide°
- Dolutegravir/lamivudine/tenofovir disoproxil°#
- Dolutegravir/rilpivirine
- Doravirine/lamivudine/tenofovir disoproxil
- Efavirenz/emtricitabine/tenofovir disoproxil#
- Efavirenz/lamivudine/tenofovir disoproxil#
- Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
- Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil
- Emtricitabine/tenofovir alafenamide
- Emtricitabine/rilpivirine/tenofovir alafenamide
- Emtricitabine/rilpivirine/tenofovir disoproxil
- Emtricitabine/tenofovir disoproxil#
- Lamivudine/nevirapine/stavudine
- Lamivudine/nevirapine/zidovudine
- Lamivudine/raltegravir
- Lamivudine/tenofovir disoproxil#
- Lamivudine/zidovudine#
- Lopinavir/ritonavir#
Uncoating inhibitors |
|
---|---|
Transcription inhibitors |
|
Translation inhibitors | |
BNAbs | |
Other | |
Failed agents |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III